Orbital Diseases: Clinical Trials

32 trials for Orbital Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed, 9 recruiting, 3 not yet recruiting, 2 active not recruiting. 32 Phase 1, 13 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 132Completed 15, Recruiting 9, Not yet recruiting 3, Active not recruiting 2, Terminated 1, Unknown 1, Withdrawn 1
Phase 213Completed 7, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1, Withdrawn 1

Follow Orbital Diseases: new trials by email Literature Review of Orbital Diseases trials Research Report on Orbital Diseases

Trials (filtered) newest first · largest first

All 32 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD)
REGN24493, Placebo - Graves' Disease
Phase 1Not yet recruitingRegeneron Pharmaceuticals452026-11-022026-10-06
Study of Atorvastatin and Its Effects in Clinical and Radiological Aspects in Patients With Moderate-to-Severe Thyroid Eye Disease
Atorvastatin, methylprednisolone (IVMP) - Thyroid Eye Disease, Graves Ophthalmopathy
Phase 1Not yet recruitingBanu Aji Dibyasakti642026-08-302026-08-13
Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease
ETHY-001, Placebo - Thyroid Eye Disease (TED), Graves' Disease
Phase 1RecruitingEthyreal Bio, Inc.722026-07-062026-10-26
A Study of IBI3031 in Participants With Thyroid Eye Disease
IBI3031, placebo - Thyroid Eye Disease
Phase 1RecruitingInnovent Biologics (Suzhou) Co. Ltd.662026-06-302026-07-14
A Clinical Study of Cizutamig in Thyroid Eye Disease
Cizutamig will be dosed according to the protocol. - Thyroid Eye Disease, TED
Phase 1RecruitingCandid Therapeutics382026-05-082026-09-01
A Study of VV-14305 for the Treatment of Thyroid Eye Disease
VV-14305, Sham (No Treatment) - Thyroid Eye Disease (TED)
Phase 1 / Phase 2RecruitingKriya Therapeutics, Inc.1352026-05-012026-08-27
An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)
NTB003, NTB003 and Placebo - Thyroid Eye Disease
Phase 1 / Phase 2Not yet recruitingNanjing Chia-tai Tianqing Pharmaceutical742026-03-012026-03-10
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
MER511 (IV), Placebo comparator (IV), MER511 (SC) - Graves Disease
Phase 1RecruitingMerida Biosciences1002025-12-192026-10-29
A Study of GensSci098 in Subjects With Graves' Disease
GenSci098 - Safety, Tolerability
Phase 1RecruitingChangchun GeneScience Pharmaceutical Co., Ltd.242025-11-212026-02-17
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants
Teprotumumab, Placebo - Healthy Volunteers
Phase 1CompletedAmgen202025-08-262026-02-27
Study of BHV-1300 in Graves' Disease
BHV-1300 - Graves Disease
Phase 1RecruitingBiohaven Therapeutics Ltd.152025-08-212026-07-31
Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)
Kamuvudine-9 - Thyroid Eye Disease
Phase 1TerminatedPeter Timoney42024-11-062026-04-01
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
GenSci098, GenSci098 Placebo - Safety, Tolerability
Phase 1RecruitingChangchun GeneScience Pharmaceutical Co., Ltd.762024-09-242026-02-11
A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease
Lu AG22515 - Thyroid Eye Disease
Phase 1Active not recruitingH. Lundbeck A/S202024-09-192026-09-09
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
AMG 732, Placebo - Thyroid Eye Disease
Phase 1 / Phase 2Active not recruitingAmgen942024-05-302026-08-10
Study of ZB001 in Chinese Patients With Thyroid Eye Disease
ZB001 for injection - Thyroid Eye Disease
Phase 1CompletedZenas BioPharma (USA), LLC172023-05-102025-04-11
A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants
Teprotumumab - Healthy Volunteers
Phase 1CompletedAmgen442023-03-242024-11-05
Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
lonigutamab, Placebo - Thyroid Eye Disease
Phase 1 / Phase 2CompletedACELYRIN Inc.312023-02-142025-07-01
A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease
Teprotumumab - Thyroid Eye Disease
Phase 1CompletedAmgen162022-07-142024-06-21
A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease
LASN01, Placebo - Pulmonary Fibrosis, Thyroid Eye Disease
Phase 1 / Phase 2CompletedLassen Therapeutics 1 PTY LTD752022-06-062024-12-30

Showing 20 of 32. Sign in to see all of them.

Narrower conditions

Graves Ophthalmopathy (21)  ·  Graves Disease (13)  ·  Autoimmune Diseases (4)  ·  Hyperthyroidism (4)  ·  Thyroid Diseases (4)  ·  Endocrine System Diseases (3)  ·  Eye Diseases (3)  ·  Eye Diseases, Hereditary (2)  ·  Immune System Diseases (2)  ·  Autoimmune Pancreatitis (1)  ·  Cardiovascular Abnormalities (1)  ·  Exophthalmos (1)  ·  Goiter (1)  ·  Inflammation (1)

Broader conditions

Exophthalmos (29)  ·  Eye Diseases (29)  ·  Goiter (29)  ·  Immune System Diseases (29)  ·  Autoimmune Diseases (27)  ·  Endocrine System Diseases (27)  ·  Hyperthyroidism (26)  ·  Thyroid Diseases (26)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (22)  ·  Genetic Diseases, Inborn (21)  ·  Eye Diseases, Hereditary (19)  ·  Graves Disease (17)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)

Interventions

Rituximab (4)  ·  teprotumumab (4)  ·  Atorvastatin (1)  ·  Azithromycin (1)  ·  Chlortetracycline (1)  ·  Dexamethasone (1)  ·  Doxycycline (1)  ·  Immunization (1)  ·  Injections (1)  ·  Methimazole (1)  ·  Methylprednisolone (1)  ·  salicylhydroxamic acid (1)  ·  sulfadiazine, tetroxoprim drug combination (1)

Sponsors

Amgen (5)  ·  Changchun GeneScience Pharmaceutical Co., Ltd. (2)  ·  ACELYRIN Inc. (1)  ·  AV7 Limited (1)  ·  Apitope International NV (1)  ·  Banu Aji Dibyasakti (1)  ·  Biohaven Therapeutics Ltd. (1)  ·  Candid Therapeutics (1)  ·  Ethyreal Bio, Inc. (1)  ·  Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1)  ·  H. Lundbeck A/S (1)  ·  Innovent Biologics (Suzhou) Co. Ltd. (1)  ·  Kriya Therapeutics, Inc. (1)  ·  Lassen Therapeutics 1 PTY LTD (1)  ·  Massachusetts General Hospital (1)

Countries

United States (12)  ·  China (9)  ·  Australia (4)  ·  Italy (2)  ·  Poland (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Bosnia and Herzegovina (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  Denmark (1)  ·  France (1)  ·  Germany (1)  ·  Greece (1)  ·  Hong Kong (1)

Top investigators

Arezou Khosroshahi, MD (1)  ·  Dan Liang, MD (1)  ·  Daniel El-Fassi, MD (1)  ·  Dave Singh, Professor (1)  ·  Eric B Suhler, MD (1)  ·  Hadas Kalish, MD (1)  ·  Huifang Zhou, PHD (1)  ·  James T Rosenbaum, MD (1)  ·  John H Stone, MD, MPH (1)  ·  Mario Salvi, MD (1)  ·  Peter Timoney (1)  ·  Rona Z Silkiss, MD (1)  ·  Simon HS Pearce (1)

Results publications

PMID 18299459, PMID 19850691, PMID 22219499, PMID 24652467, PMID 25667206, PMID 26221138, PMID 42660999

NIH funding

2023 (1), 2025 (1)